OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer – Beyond the Abstract
Non-Muscle-Invasive Bladder Cancer (NMIBC), OncoTherad (MRB-CFI-1), Nanoimmunotherapy, Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer treatment, BCG unresponsive disease, T-Cell CX3CR1, Toll-Like Receptor 4 Signaling Pathway, cytotoxic T cells, tumor microenvironment (TME).